Navigation Links
Sanofi and Regeneron Launch Comprehensive Phase 3 Clinical Program With LDL Cholesterol-Lowering PCSK9 Antibody
Date:7/19/2012

-on therapy in patients with primary hypercholesterolemia at high cardiovascular risk or with heFH who are not adequately controlled on statins, in comparison to several second line lipid lowering strategies.
  • ODYSSEY LONG TERM: The primary objective of this study is to evaluate the long-term safety and tolerability of SAR236553/REGN727 in patients with hypercholesterolemia at high cardiovascular risk or patients with heFH inadequately controlled with their current lipid-modifying therapy.

  • In addition, the ODYSSEY program will also include ODYSSEY OUTCOMES, a Phase 3 cardiovascular outcomes trial which will enroll about 18,000 patients and evaluate the effect of SAR236553/REGN727 on the occurrence of cardiovascular events.

    Further information about the initiated Phase 3 studies can be found at http://www.clinicaltrials.gov.

    About Sanofi

    Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs.  Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

    About Regeneron Pharmaceuticals, Inc.

    Regeneron is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.  Regeneron markets two products in the United States, EYLEA® (aflibercept) Injection and ARCALYST® (rilonacept) Injection for Subcutaneous Use.  Regeneron has filed regulatory applications with the U.S. Food and Drug Administration (FDA) for second indications for EYLEA and ARCALYST and for the product candidate ZALTRAP® (aflibercept)
    '/>"/>

    SOURCE Sanofi and Regeneron Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related biology technology :

    1. Sanofi Signs Agreement for Type 1 Diabetes Research with Boston Academic Teaching Hospital
    2. Collaboration between Sanofi and Joslin Diabetes Center to focus on new drugs for diabetes
    3. Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet
    4. Former Sanofi-aventis and US Oncology Executive Joins New Century Health as Chief Executive Officer
    5. PharmaVentures Client Sanofi Wins Scrip Outsourcing Deal of the Year Award
    6. Regeneron Announces March 2012 Investor Conference Presentations
    7. Regeneron Announces Presentation at the Leerink Swann 2012 Global Healthcare Conference
    8. Elsevier Launches International Journal for Parasitology: Parasites and Wildlife
    9. Elsevier Launches a New Product Literature Database Solution for Life Science Professionals
    10. GenoSpace Announces the Launch of a Cloud-Based "Information Ecosystem" for Advancing 21st-Century Personalized Medicine
    11. infirst HEALTHCARE Established to Launch Novel Consumer Medicines
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/28/2014)... July 28, 2014 Research and Markets ... Synthetic Biology Market 2014-2018" report to their offering. ... The term synthetic biology covers the designing and engineering ... well as the redesigning of natural biological systems that ... be a form of extreme genetic engineering because it ...
    (Date:7/28/2014)... 28, 2014 According ... Market by Products (Consumables, Instruments, Services), Methods (Phenotypic, Genotypic), Applications (Pharmaceutical, ... (Detection, Characterization) - Global Forecasts to 2019" ... is estimated at $896.5 Million in 2014 ... by 2019, growing at a CAGR of ...
    (Date:7/28/2014)... Boston, MA (PRWEB) July 28, 2014 ... with two researchers to further develop potential treatments for ... brain tumor, in combination with their patented vaccine platform, ... and Duke University, are based on the work of ... of Neurosurgery at The Preston Robert Tisch Brain Tumor ...
    (Date:7/28/2014)... St Louis, MO (PRWEB) July 28, 2014 ... tools, software, and services that bring the power of ... for the inaugural Appistry Pipeline Challenge . ... Callum Bell, president of the National Center for Genome ... Children’s Mercy Hospitals and Clinics of Kansas City. Rounding ...
    Breaking Biology Technology:Global Synthetic Biology Market 2014-2018 2Microbial Identification Market worth $1,194.1 Million by 2019 2Microbial Identification Market worth $1,194.1 Million by 2019 3String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 2String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 3String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 4Appistry Names Industry Experts from the National Center for Genome Resources and Mercy Children's, Kansas City, to Judge Pipeline Challenge Competition 2
    ... 7, 2011 Reportlinker.com announces that a new ... Industrial Biotechnology China News 1103 ... The Chinese central government was reported to continue ... the Twelfth Five-Year (2011-2015) Plan. This act is ...
    ... and industrial research scientists and engineers, as well ... encounter a steep learning curve when developing common ... book just published by Springer promises to be ... The new MEMS Materials and Processes Handbook is ...
    ... The U.S. Food and Drug Administration today approved ... tool to treat brain aneurysms without performing open surgery. ... An aneurysm is a weak, enlarged area in an ... blood pressure can cause it to rupture, which can ...
    Cached Biology Technology:Reportlinker Adds Industrial Biotechnology China News 1103 2Reportlinker Adds Industrial Biotechnology China News 1103 3MEMS Materials and Processes Handbook -- a comprehensive, practical resource 2FDA Approves New Device to Treat Brain Aneurysms 2FDA Approves New Device to Treat Brain Aneurysms 3
    (Date:7/28/2014)... advance the genetic engineering of "fuel" crops for ... by researchers with the U.S. Department of Energy ... led by Lawrence Berkeley National Laboratory (Berkeley Lab). ... enables scientists to identify and characterize the function ... biosynthesis of plant cell walls. , "Our unique ...
    (Date:7/28/2014)... virus killers to prevent and treat HIV infection has ... response these molecules can arouse as they get rid ... at the Weizmann Institute and the National Institutes of ... these molecules interferons around the time of ... the disease. Their research appeared in Nature . ...
    (Date:7/28/2014)... Institute for Biologically Inspired Engineering at Harvard University ... be commercialized by a newly formed private company ... personalized medicine products. The announcement follows ... Technology Development (OTD) and the start-up Emulate Inc., ... human Organs-on-Chips platform. , "This is a ...
    Breaking Biology News(10 mins):How sweet it is 2How sweet it is 3Interfering with interferon 2Wyss Institute's technology translation engine launches 'Organs-on-Chips' company 2Wyss Institute's technology translation engine launches 'Organs-on-Chips' company 3
    ... light, Stacie Grassano pulls out a tube. "This is a great ... Inside, a tree branch is speckled with white fluff. "It's growing ... brings the branch close to his eye. "Yes," he says, with ... For some, a fungus success story means nothing is growing at ...
    ... reveal in the 29 March 2007 issue of the ... important structures that control how genes are packaged and ... time, we are seeing in very high resolution on ... an organism's genes," said B. Franklin Pugh, professor of ...
    ... into a box glowing with fluorescent light, Stacie Grassano pulls out ... clear plastic up to her face. Inside, a tree branch is ... it to Scott Costa. , Costa brings the branch close to ... a fungus success story." , For some, a fungus success ...
    Cached Biology News:Immunization rates hit record high in poor countries 2Immunization rates hit record high in poor countries 3Scientists reveal structure of gateways to gene control 2Scientists reveal structure of gateways to gene control 3Scientists reveal structure of gateways to gene control 4Fungal factories may save hemlock forests 2Fungal factories may save hemlock forests 3